



FOR IMMEDIATE RELEASE

**SUSTAINED NANO SYSTEMS SELECTED TO PRESENT AT
THE BIOTECH SHOWCASE IN SAN FRANCISCO
January 9, 2019**

New York, NY – December 20, 2018 (NEWSFRONT MEDIA). Sustained Nano Systems, LLC (“SNS”) a privately-held biopharmaceutical company utilizing bio-resorbable nano and microparticles for long term drug delivery, has been selected as one of seven emerging growth companies to present at the Bio Tech Showcase in San Francisco, January 7-9, 2019.

The Company will report on the effectiveness of its Sustained Platform Technology to deliver extended duration of bioactive small and macromolecules utilizing bio-resorbable nano and microparticles. SNS studies indicate that its ability to deliver a one-time dose that provides drug coverage from weeks to years as prescribed, could help assure that full compliance is achieved without the inherent difficulties of long term patient self-medication.

The Company is initiating clinical studies of its once administered drug, for the prevention and treatment of ocular inflammation following cataract surgery, replacing multiple eye drop dosing, with a projected approval in Q2, 2020.

SNS will also present results on its once administered glaucoma drug with a duration of six months, replacing a life time of eye drops, and its one year in-vivo results for retinal disease following the single administration of bevacizumab (Avastin), a monoclonal antibody, replacing the present dosing of 6-8 intravitreal injections each year.

SNS believes that the need to provide long term delivery of large molecules, such as monoclonal antibodies, through the SNS Platform Technology has the potential to provide a new therapeutic alternative to short term, multiple dosing of pharmaceutical agents.

ABOUT SUSTAINED NANO SYSTEMS (SNS)

SNS is a privately held biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions in ophthalmology, oncology and other areas. The Company's research facility is located on the campus of Stony Brook University as part of the Long Island High Technology Incubator. The SNS platform is the result of a comprehensive research effort that allows for long term micro-dosing for the continuous release of drugs to targeted tissues as prescribed. The basis of the SNS pipeline is its patented technology that incorporates bio-resorbable nano and micro carriers to deliver a wide variety of drugs that offer both enhanced drug release kinetics and high dose capacity. Such drug delivery is especially needed in ophthalmology, oncology, inflammatory conditions, neurologic disorders, and dermatology. SNS is seeking licensing, joint ventures and financing to support its research and development programs.

For further information, visit: www.sustainednanosystems.net

Forward-Looking Statements

SNS Disclosure Notice: This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein or which are otherwise made by or on behalf of the Company that are not statements of historical facts may be deemed forward looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "should," "would," "estimate," or "continue," or the negative or other variations thereof or comparable terminology are intended to identify forward looking statements. Investors are cautioned that all forward looking statements involve risk and uncertainties which may cause results to differ materially from those set forth in the statements. Such risks and uncertainties include, but are not limited to the following: the success of research and development activities and the speed with which regulatory authorizations and product launches may be achieved; government regulation generally; competitive developments; the ability to successfully market products domestically and internationally; difficulties or delays in manufacturing or issues relating to manufacturing capacity; commercial obstacles to the successful introduction of brand products generally; legal defense costs, insurance expenses, settlement costs, and the risk of an adverse decision or settlement relating to product liability, patent protection, governmental investigations, and other legal proceedings; the Company's ability to acquire and protect patents and other intellectual property both domestically and internationally; the absence of certainty regarding the receipt of required regulatory approval or the timing or terms of such approvals; any changes in business,

political and economic conditions; business interruption due to hurricanes or other events outside of the Company's control.

Investors are cautioned not to place reliance on these forward-looking statements, which are valid only as of the date they were made. The Company undertakes no obligation to update or revise any forward-looking statements to reflect new information or the occurrence of unanticipated events or otherwise, except as expressly required by law.

Contact:

Dr. Barry Libin

[\(516\) 353-7983](tel:5163537983)

barlibin@gmail.com

New York, NY – November 28, 2018 (NEWSFRONT MEDIA). Sustained Nano Systems, LLC (“SNS”) a privately-held biopharmaceutical company utilizing bio-resorbable nano and microparticles for long term drug delivery for ocular inflammation, glaucoma and retinal disease, is one of seven emerging growth companies selected to present at the Bio Tech Showcase in San Francisco, January 7-9, 2019. The Bio-Tech Showcase is presented in tandem with the annual JP Morgan Healthcare Conference, the largest healthcare investment symposium in the world, bringing together over 10,000 attendees, including industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.

Dr. Barry Libin, CEO of SNS, will report on the effectiveness of the SNS Sustained Platform Technology to deliver extended duration of bioactive macromolecules for retinal disease, including its one year in-vivo results following the single administration of bevacizumab (Avastin), a monoclonal antibody. The Company is now preparing for initiation of its first clinical study for the prevention of ocular inflammation following cataract surgery and developing its one time administered, 6-month duration drug to treat glaucoma.

SNS believes that the need to provide long term delivery of monoclonal antibodies through the SNS Platform Technology has the potential to provide a new therapeutic alternative to short term, multiple dosing of pharmaceutical agents. SNS studies indicate that its ability to deliver a one-time dose that provides drug coverage from weeks to months as prescribed, could help assure that full compliance is achieved without the inherent difficulties of long term patient self-medication.

ABOUT SUSTAINED NANO SYSTEMS (SNS)

SNS is a privately held biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions in ophthalmology, oncology and other areas. The Company's research facility is located on the campus of Stony Brook University as part of the Long Island High Technology Incubator. The SNS platform is the result of a comprehensive research effort that allows for long term micro-dosing for the continuous release of drugs to targeted tissues as prescribed. The basis of the SNS pipeline is its patented technology that incorporates bio-resorbable nano and micro carriers to deliver a wide variety of drugs that offer both enhanced drug release kinetics and high dose capacity. Such drug delivery is especially needed in ophthalmology, oncology, inflammatory conditions,

neurologic disorders, and dermatology. SNS may seek licensings, acquisitions, partnerships, joint ventures and/or public and private financings to accelerate and provide additional funding to support its research and development programs.

For further information, visit: www.sustainednanosystems.net

Forward-Looking Statements

SNS Disclosure Notice: This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein or which are otherwise made by or on behalf of the Company that are not statements of historical facts may be deemed forward looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “to,” “plan,” “expect,” “believe,” “anticipate,” “intend,” “could,” “should,” “would,” “estimate,” or “continue,” or the negative or other variations thereof or comparable terminology are intended to identify forward looking statements. Investors are cautioned that all forward looking statements involve risk and uncertainties which may cause results to differ materially from those set forth in the statements. Such risks and uncertainties include, but are not limited to the following: the success of research and development activities and the speed with which regulatory authorizations and product launches may be achieved; government regulation generally; competitive developments; the ability to successfully market products domestically and internationally; difficulties or delays in manufacturing or issues relating to manufacturing capacity; commercial obstacles to the successful introduction of brand products generally; legal defense costs, insurance expenses, settlement costs, and the risk of an adverse decision or settlement relating to product liability, patent protection, governmental investigations, and other legal proceedings; the Company’s ability to acquire and protect patents and other intellectual property both domestically and internationally; the absence of certainty regarding the receipt of required regulatory approval or the timing or terms of such approvals; any changes in business, political and economic conditions; business interruption due to hurricanes or other events outside of the Company’s control.

Investors are cautioned not to place reliance on these forward-looking statements, which are valid only as of the date they were made. The Company undertakes no obligation to update or revise any forward-looking statements to reflect new information or the occurrence of unanticipated events or otherwise, except as expressly required by law.

Contact:

Dr. Barry Libin
[\(516\) 353-7983](tel:5163537983)
barlibin@gmail.com

Media Relations
info@newsfrontmedia.com

You are subscribed to Sustained Nano Systems, LLC Investor Relations e-mail alerts:
To unsubscribe please send to info@newsfrontmedia.com

Dr. Barry Libin, CEO of SNS, will report on the effectiveness of the SNS Sustained Platform Technology to deliver extended duration of bioactive macromolecules for retinal disease, including its one year in-vivo results following the single administration of bevacizumab (Avastin), a monoclonal antibody. The Company is now

preparing for initiation of its first clinical study for the prevention of ocular inflammation following cataract surgery and developing its one time administered, 6-month duration drug to treat glaucoma.

SNS believes that the need to provide long term delivery of monoclonal antibodies through the SNS Platform Technology has the potential to provide a new therapeutic alternative to short term, multiple dosing of pharmaceutical agents. SNS studies indicate that its ability to deliver a one-time dose that provides drug coverage from weeks to months as prescribed, could help assure that full compliance is achieved without the inherent difficulties of long term patient self-medication.

ABOUT SUSTAINED NANO SYSTEMS (SNS)

SNS is a privately held biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions in ophthalmology, oncology and other areas. The Company's research facility is located on the campus of Stony Brook University as part of the Long Island High Technology Incubator. The SNS platform is the result of a comprehensive research effort that allows for long term micro-dosing for the continuous release of drugs to targeted tissues as prescribed. The basis of the SNS pipeline is its patented technology that incorporates bio-resorbable nano and micro carriers to deliver a wide variety of drugs that offer both enhanced drug release kinetics and high dose capacity. Such drug delivery is especially needed in ophthalmology, oncology, inflammatory conditions, neurologic disorders, and dermatology. SNS may seek licensings, acquisitions, partnerships, joint ventures and/or public and private financings to accelerate and provide additional funding to support its research and development programs.

For further information, visit: www.sustainednanosystems.net

Forward-Looking Statements

SNS Disclosure Notice: This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein or which are otherwise made by or on behalf of the Company that are not statements of historical facts may be deemed forward looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "should," "would," "estimate," or "continue," or the negative or other variations thereof or comparable terminology are intended to identify forward looking statements. Investors are cautioned that all forward looking statements involve risk and uncertainties which may cause results to differ materially from those set forth in the statements. Such risks and uncertainties include, but are not limited to the following: the success of research and development activities and the speed with which regulatory authorizations and product launches may be achieved; government regulation generally; competitive developments; the ability to successfully market products domestically and internationally; difficulties or delays in manufacturing or issues relating to manufacturing capacity; commercial obstacles to the successful introduction of brand products generally; legal defense costs, insurance expenses, settlement costs, and the risk of an adverse decision or settlement relating to product

liability, patent protection, governmental investigations, and other legal proceedings; the Company's ability to acquire and protect patents and other intellectual property both domestically and internationally; the absence of certainty regarding the receipt of required regulatory approval or the timing or terms of such approvals; any changes in business, political and economic conditions; business interruption due to hurricanes or other events outside of the Company's control.

Investors are cautioned not to place reliance on these forward-looking statements, which are valid only as of the date they were made. The Company undertakes no obligation to update or revise any forward-looking statements to reflect new information or the occurrence of unanticipated events or otherwise, except as expressly required by law.

Contact:
Dr. Barry Libin
[\(516\) 353-7983](tel:(516)353-7983)
barlibin@gmail.com

Media Relations
info@newsfrontmedia.com

You are subscribed to Sustained Nano Systems, LLC Investor Relations e-mail alerts:

To unsubscribe please send to info@newsfrontmedia.com